Lenvatinib (Lenvatinib) belongs to which generation of targeted drugs?

Lenvatinib (Lenvatinib) is an oral multikinase inhibitor and a second-generation targeted drug. Targeted drugs refer to drugs that can selectively intervene against specific molecular targets in tumor cells, thereby inhibiting tumor growth and spread.

The first generation of targeted drugs mainly include drugs that interfere with targets such as EGFR (epidermal growth factor receptor) and VEGFR (vascular endothelial growth factor receptor), such as gefitinib (Gefitinib), erlotinib (Erlotinib), etc., have played a positive role in tumor treatment, but they also have some limitations, such as the susceptibility to drug resistance.

With in-depth research on tumor biology and drug action mechanisms, the second generation of targeted drugs has gradually emerged. Lenvatinib is one of them. Second-generation targeted drugs have broader targets, stronger anti-tumor activity and better pharmacokinetic properties than first-generation drugs. Lenvatinib (Lenvatinib) mainly inhibits the activity of multiple receptor tyrosine kinases (RTKs), including VEGFR1, < /span>VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, PDGFRα, KIT, and RET, etc., play a role in tumor angiogenesis and growth factor pathways, thereby inhibiting tumor angiogenesis and growth.

The second-generation targeted drugs have also improved drug resistance compared with the first-generation drugs, but they also have some adverse reactions and drug resistance problems. Therefore, current research is also constantly exploring third-generation and higher-level targeted drugs to improve the effect of tumor treatment and reduce the side effects of drugs.

Overall,Lenvatinib As a second-generation targeted drug, it has achieved certain results in the treatment of various malignant tumors such as thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma, and provides patients with new treatment options. With the continuous advancement of science and technology and the deepening of clinical research, it is believed that the role of targeted drugs in tumor treatment will become more and more obvious, bringing more hope to patients.